ISN Journal summaries on CKD-MBD, Pexivas trial, in-center hemodialysis, and the ISN Collaborative Quality Framework on Dialysis
Kidney International® (KI)
The 2023 KDIGO conference confirmed that the 2017 guidelines on managing chronic kidney disease–mineral and bone disorder (CKD-MBD) remain valid but proposed reframing CKD-MBD around two clinical syndromes: CKD-associated osteoporosis and CKD-associated cardiovascular disease.
Future guidelines may incorporate personalized care using bone turnover biomarkers, refined calcium assessments, and AI tools to guide clinical decisions.
A post-hoc analysis of the PEXIVAS trial showed that PLEX improved early kidney function in ANCA-associated vasculitis, with the greatest benefit seen at four weeks, while reduced glucocorticoid dosing had no significant effect on kidney recovery.
These findings support using PLEX to enhance early kidney recovery and may guide personalized treatment strategies for patients with ANCA-associated glomerulonephritis.
Kidney International Reports® (KIR)
A nationwide study found that patients in Aotearoa, New Zealand, living farther from dialysis units, especially in rural areas, were less likely to receive in-center hemodialysis, with significant regional variation in travel times and unit capacity.
The authors suggest that geospatial mapping can guide targeted service planning to reduce travel burdens and improve dialysis access, particularly in underserved rural areas.
The ISN Collaborative Quality Framework sets minimum standards for safe dialysis, linking them to resource requirements and reporting tools. It emphasizes patient safety, transparency, and continuous quality improvement while allowing flexibility based on local resources.
This framework aims to guide policymakers, providers, and patient groups in improving dialysis care worldwide, with ongoing revisions based on real-world implementation and feedback.
